Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Science Strategy

TORONTO, February 08, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”)a drug discovery and development company focused on creating optimized, patentable next-generation psychedelic drugs to treat neurological and psychiatric disorders with unmet medical needs, announced today that it has appointed Fiona Randall, BSc., Ph.D., a neuroscientist by training with global research and management experience, as senior vice president of external alliances and science strategy.

“We have a tremendous opportunity to accelerate Mindset’s growth through strategic partnerships. With Dr. Randall’s extensive experience in neurological research and managing and executing alliances, we are thrilled to have her join our team,” said Jacques Lanthier, CEO of Mindset. “Dr. Randall’s industry network and history of successfully managing complex and diverse alliances will play a critical role in developing future collaborations for our new families of next-generation psychedelic compounds.

More recently, Dr Randall based FireWire Consulting LLC which provides preclinical research and commercial development services to biopharmaceutical companies. She also served as Senior Director and Acting Head of Alliance Management at Vertex Pharmaceuticals Inc. and Head of External Innovation at Eisai Inc. focusing on how partner organizations combine their strengths to develop innovative therapies for patients across a range of diseases. Dr Randall is a renowned scientist with industrial research experience with Eisai, GSK and Merck and has worked in the United States, UK, China and Japan.

“I am delighted to join Mindset at this crucial stage in the company’s remarkable growth journey. Mindset’s approach to drug development is rooted in scientific rigor and its platform of optimized psychedelic compounds expands the possibilities of delivering mental health solutions both in the clinic and at home. Patients are at the heart of my scientific interests and I am excited to return to work in neurology to manufacture medicines for people living with debilitating mental health conditions. I look forward to collaborating with the company’s talented team and our strategic partner organizations to accelerate the development of Mindset’s strong portfolio of next-generation psychedelic compounds,” said Dr Randall.

On Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized, patentable next-generation psychedelic drugs to treat neurological and psychiatric disorders with unmet needs. Mindset was created to develop next-generation pharmaceutical actives that harness the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several new families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. The company has a co-development agreement with the McQuade Center for Strategic Research and Developmentmember of the Otsuka Pharmaceuticals corporate family, for its short-lived compounds, Mindset Families 2 & 4.

For more information about Mindset, please visit our website at www.mindsetpharma.com.

For more information please contact:

Investor contacts:Allison Sos/Tim ReganKCSA Strategic Communications
Email: [email protected]
Phone: 212-896-1267/ 347-487-6788

Media Contact:McKenna MillerKCSA Strategic Communications
Email: [email protected]
Phone: 949-606-6585

Company Contact:Jacques LanthierCEO
Email: [email protected]

Jason Atkinsonvice president, corporate development
Email: [email protected]
Phone: 416-479-4094

Forward-looking information
This press release contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management as of the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results actuals differ materially from those projected in the forward-looking information. information search. Additional information regarding the risks and uncertainties relating to the Company’s business can be found under the heading “Risk Factors” in the Company’s Annual Information Form for the year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required. by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE SUITABILITY OR ACCURACY OF THIS RELEASE.

main logo

Source: Mindset Pharma Inc.

2022 GlobeNewswire, Inc., source Press releases – Canada

Shirlene J. Manley